Soleus Capital Management’s Viking Therapeutics VKTX Stock Holding History

Soleus Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-70,000	Closed	-$2.46M	–	115
2025 Q4	$2.46M	Buy	+70,000	New	+$2.48M	0.09%	77
2024 Q2	–	Sell	-67,121	Closed	-$5.5M	–	113
2024 Q1	$5.5M	Sell	67,121 -369,079	-85%	-$16.4M	0.41%	64
2023 Q4	$8.12M	Buy	436,200 +314,000	+257%	+$4.11M	0.9%	36
2023 Q3	$1.35M	Sell	122,200 -214,500	-64%	-$3.07M	0.12%	75
2023 Q2	$5.46M	Sell	336,700 -123,300	-27%	-$2.58M	0.61%	46
2023 Q1	$7.66M	Buy	+460,000	New	+$4.75M	0.79%	36

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Soleus Capital Management's VKTX Position: Q1 2026 in Review

Soleus Capital Management sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 70,000 shares — an estimated $2.46M sold.

Soleus Capital Management first reported a position in VKTX in Q1 2023 and held it in 6 quarters. The position peaked at $8.12M in Q4 2023. 414 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Soleus Capital Management reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
Soleus Capital Management sold 70,000 Viking Therapeutics shares in Q1 2026, an estimated $2.46M.
Soleus Capital Management first reported a position in Viking Therapeutics in Q1 2023 and held it in 6 quarters.
Soleus Capital Management's Viking Therapeutics position peaked at $8.12M in Q4 2023.
414 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.